Hyderabad: Dr Reddy’s Laboratories on Friday said it has reached the third stage of clinical trial for an anti-diabetic drug, which could become the first innovative molecule from India.
The company also said it has completed the first stage of human trials for an anti-cholesterol compound with promising results.
The anti-diabetic compound ‘Balagletazone´ has reached phase III clinical trial stage and has the “potential to become the first innovative molecule from India,” Dr Reddy’s Laboratories founder K Anji Reddy told reporters here today.
He said the company is also working on a new cholesterol lowering compound.
“We are developing an anti-cholesterol compound, which is showing a very promising potential. We have just concluded our Phase I clinical trials,” Reddy said.
He, however, did not specify where the trials are being done and by when it could go to the next stage.
Phase I clinical trials are the first stage of testing in human subjects on a select small number of volunteers (20-50), while the phase III trials are conducted on larger randomized sample of up to 3,000.
He claimed that the new anti-cholesterol compound has the potential of becoming a blockbuster drug and many other multinational firms were also working on it.